Analysis of the IDH1 codon 132 mutation in brain tumors

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · see citing works

A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium

RAFF, M. C., Miller, R. H., & Noble, M. (1983) · Nature · doi:10.1038/303390a0 · Cited by 2,030 · see citing works

Overexpression of the EGF Receptor and p53 Mutations are Mutually Exclusive in the Evolution of Primary and Secondary Glioblastomas

Watanabe, K., Tachibana, O., Sato, K., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (1996) · Brain Pathology · doi:10.1111/j.1750-3639.1996.tb00848.x · Cited by 739 · see citing works

Cytosolic NADP+-dependent isocitrate dehydrogenase status modulates oxidative damage to cells

Lee, S. M., Koh, H., Park, D., Song, B. J., Huh, T., & Park, J. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00815-8 · Cited by 422 · see citing works

Subsets of Glioblastoma Multiforme Defined by Molecular Genetic Analysis

von Deimling, A., Ammon, K. V., Schoenfeld, D., Wiestler, O. D., Seizinger, B. R., & Louis, D. N. (1993) · Brain Pathology · doi:10.1111/j.1750-3639.1993.tb00721.x · Cited by 331 · see citing works

Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities.

Ichimura, K., Bondesson, M., Goike, H., Schmidt, E., Moshref, A., & Collins, V. P. (2000) · PubMed · Cited by 282 · see citing works

Novel Molecular Signaling and Classification of Human Clinically Nonfunctional Pituitary Adenomas Identified by Gene Expression Profiling and Proteomic Analyses

Moreno, C. S., Evans, C.-O., Zhan, X., Okor, M., Desiderio, D. M., & Oyesiku, N. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0884 · Cited by 229 · see citing works

Impact of Genotype and Morphology on the Prognosis of Glioblastoma

Schmidt, M. C., Antweiler, S., Urban, N., Mueller, W. C., Kuklik, A., Meyer‐Puttlitz, B., Wiestler, O. D., Louis, D. N., Fimmers, R., & von Deimling, A. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.4.321 · Cited by 211 · see citing works

The Human PICD Gene Encodes a Cytoplasmic and Peroxisomal NADP+-dependent Isocitrate Dehydrogenase

Geisbrecht, B. V., & Gould, S. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.43.30527 · Cited by 189 · see citing works

Effects of Colchicine and Radiation on Growth of Normal Tissues and Tumors

Brues, A. M., Marble, B. B., & Jackson, E. B. (1940) · American Journal of Cancer · doi:10.1158/ajc.1940.159 · Cited by 183 · see citing works

Genetic Signature of Oligoastrocytomas Correlates with Tumor Location and Denotes Distinct Molecular Subsets

Mueller, W. C., Hartmann, C. J., Hoffmann, A., Lanksch, W., Kiwit, J. C. W., Tonn, J. C., Veelken, J., Schramm, J., Weller, M., Wiestler, O. D., et al. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64183-1 · Cited by 178 · see citing works

Comprehensive Allelotype and Genetic Analysis of 466 Human Nervous System Tumors

von Deimling, A., Fimmers, R., Schmidt, M. C., Bender, B., Faßbender, F., Nagel, J., Jahnke, R., Kaskel, P., Duerr, E., Koopmann, J., et al. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.6.544 · Cited by 152 · see citing works

Molecular genetic analysis of giant cell glioblastomas.

Meyer‐Puttlitz, B., Hayashi, Y., Waha, A., et al. (1997) · PubMed · Cited by 94 · see citing works

p53 Mutations versus EGF Receptor Expression in Giant Cell Glioblastomas

Peraud, A., Watanabe, K., Plate, K. H., et al. (1997) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199711000-00008 · Cited by 61 · see citing works

Regulation of singlet oxygen-induced apoptosis by cytosolic NADP+-dependent isocitrate dehydrogenase

Kim, S.-Y., Lee, S. M., Tak, J. K., Choi, K. S., Kwon, T. K., & Park, J. (2007) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-007-9421-x · Cited by 61 · see citing works

Identification by Mutagenesis of Arginines in the Substrate Binding Site of the Porcine NADP-dependent Isocitrate Dehydrogenase

Soundar, S., Danek, B. L., & Colman, R. F. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5606 · Cited by 38 · see citing works

Expression and Mutagenesis of Mammalian Cytosolic NADP+-Specific Isocitrate Dehydrogenase

Jennings, G. T., Minard, K. I., & McAlister-Henn, L. (1997) · Biochemistry · doi:10.1021/bi970916r · Cited by 32 · see citing works

The emerging hallmarks of cancer metabolism

Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926 · see citing works

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154 · see citing works

Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma

Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337 · see citing works

IDH mutation impairs histone demethylation and results in a block to cell differentiation

Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., et al. (2012) · Nature · doi:10.1038/nature10860 · Cited by 1,985 · see citing works

Glioma-Derived Mutations in <i>IDH1</i> Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α

Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119 · see citing works

2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas

Choi, C., Ganji, S. K., DeBerardinis, R. J., Hatanpaa, K. J., Rakheja, D., Kovacs, Z., Yang, X.-L., Mashimo, T., Raisanen, J. M., Marin-Valencia, I., et al. (2012) · Nature Medicine · doi:10.1038/nm.2682 · Cited by 839 · see citing works

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

Gross, S., Cairns, R. A., Minden, M. D., Driggers, E. M., Bittinger, M. A., Jang, H. G., Sasaki, M., Jin, S., Schenkein, D. P., Su, S. M., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092506 · Cited by 736 · see citing works

Advances in the molecular genetics of gliomas — implications for classification and therapy

Reifenberger, G., Wirsching, H.-G., Knobbe-Thomsen, C. B., & Weller, M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.204 · Cited by 662 · see citing works

Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine

Zhang, J., Pavlova, N. N., & Thompson, C. B. (2017) · The EMBO Journal · doi:10.15252/embj.201696151 · Cited by 651 · see citing works

IDH1 and IDH2 mutations in gliomas

Cohen, A. L., Holmen, S. L., & Colman, H. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0345-4 · Cited by 629 · see citing works

The Mitochondrial Proteome and Human Disease

Calvo, S. E., & Mootha, V. K. (2010) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-082509-141720 · Cited by 590 · see citing works

What a difference a hydroxyl makes: mutant IDH, (<i>R</i>)-2-hydroxyglutarate, and cancer

Losman, J.-A., & Kaelin, W. G. (2013) · Genes &amp; Development · doi:10.1101/gad.217406.113 · Cited by 570 · see citing works

Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism

Reitman, Z. J., & Yan, H. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq187 · Cited by 562 · see citing works

BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1

Tönjes, M., Barbus, S., Park, Y. J., Wang, W., Schlotter, M., Lindroth, A. M., Pleier, S. V., Bai, A. H. C., Karra, D., Piro, R. M., et al. (2013) · Nature Medicine · doi:10.1038/nm.3217 · Cited by 486 · see citing works

IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection

Beiko, J., Suki, D., Hess, K. R., Fox, B. D., Cheung, V., Cabral, M., Shonka, N., Gilbert, M. R., Sawaya, R., Prabhu, S. S., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not159 · Cited by 456 · see citing works

Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities

Cairns, R. A., & Mak, T. W. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0083 · Cited by 452 · see citing works

Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion

Tateishi, K., Wakimoto, H., Iafrate, A. J., Tanaka, S., Loebel, F., Lelic, N., Wiederschain, D., Bedel, O., Deng, G., Zhang, B., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.11.006 · Cited by 433 · see citing works

Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy

Pope, W. B., Prins, R. M., Albert Thomas, M., Nagarajan, R., Yen, K. E., Bittinger, M. A., Salamon, N., Chou, A. P., Yong, W. H., Soto, H., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0737-8 · Cited by 318 · see citing works

Mitochondrial DNA variation and cancer

Kopinski, P. K., Singh, L. N., Zhang, S., Lott, M. T., & Wallace, D. C. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00358-w · Cited by 301 · see citing works

Cancer-associated IDH mutations: biomarker and therapeutic opportunities

Yen, K. E., Bittinger, M. A., Su, S. M., & Fantin, V. R. (2010) · Oncogene · doi:10.1038/onc.2010.444 · Cited by 296 · see citing works

Marked for death: Targeting epigenetic changes in cancer

Pfister, S. X., & Ashworth, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.256 · Cited by 288 · see citing works

Isocitrate dehydrogenase-1 mutations: A fundamentally new understanding of diffuse glioma?

Kloosterhof, N. K., Bralten, L. B., Dubbink, H. J., French, P. J., & van den Bent, M. J. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70053-x · Cited by 222 · see citing works

Metabolic enzymes as oncogenes or tumor suppressors

Thompson, C. B. (2009) · New England Journal of Medicine · doi:10.1056/nejme0810213 · Cited by 213 · see citing works

Isocitrate Dehydrogenase Mutation and ( <i>R</i> )-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development

Dang, L., & Su, S.-S. M. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-044732 · Cited by 204 · see citing works

Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in <i>IDH</i> -Mutant Gliomas

Wakimoto, H., Tanaka, S., Curry, W. T., Loebel, F., Zhao, D., Tateishi, K., Chen, J., Klofas, L. K., Lelic, N., Kim, J. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3052 · Cited by 190 · see citing works

2-Hydroxyglutarate in Cancer Cells

Ježek, P. (2020) · Antioxidants &amp; Redox Signaling · doi:10.1089/ars.2019.7902 · Cited by 130 · see citing works

LncRNA IDH1-AS1 links the functions of c-Myc and HIF1α via IDH1 to regulate the Warburg effect

Xiang, S., Gu, H., Jin, L., Thorne, R. F., Zhang, X. D., & Wu, M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1711257115 · Cited by 129 · see citing works

Interactions between epigenetics and metabolism in cancers

Yun, J., Johnson, J. L., Hanigan, C. L., & Locasale, J. W. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00163 · Cited by 82 · see citing works

2-HG Inhibits Necroptosis by Stimulating DNMT1-Dependent Hypermethylation of the RIP3 Promoter

Yang, Z., Jiang, B., Wang, Y., Ni, H., Zhang, J., Xia, J., Shi, M., Hung, L.-M., Ruan, J., Mak, T. W., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.012 · Cited by 78 · see citing works

Epigenome modifiers and metabolic rewiring: New frontiers in therapeutics

Ferrari, A., Longo, R., Silva, R., Mitro, N., Caruso, D., De Fabiani, E., & Crestani, M. (2019) · Pharmacology &amp; Therapeutics · doi:10.1016/j.pharmthera.2018.08.008 · Cited by 19 · see citing works

[Prognostic significance of combined TERT and IDH gene mutation analysis in diffusely infiltrating gliomas].

Liu, Q. Q., Yin, X. X., Zou, Y., et al. (2018) · PubMed · doi:10.3760/cma.j.issn.0529-5807.2018.09.002 · Cited by 1 · see citing works

Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients

Mukasa, A., Takayanagi, S., Saito, K., Shibahara, J., Tabei, Y., Furuya, K., Ide, T., Narita, Y., Nishikawa, R., Ueki, K., et al. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02175.x · Cited by 90 · see citing works

Distinct TERT promoter C228T and C250T mutations in a patient with an oligodendroglioma: A case report

Ishi, Y., Okada, H., Okamoto, M., et al. (2021) · Neuropathology · doi:10.1111/neup.12727 · Cited by 3 · see citing works

P19.02.A FUNCTIONAL CONSEQUENCES OF IDH1 AND CIC MUTATIONS ON OLIGODENDROGLIOMA CELLS OF ORIGIN

Pottier, N., Joppé, S. E., Magne, N., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad137.420

Contribution of Molecular Biology to the Classification of Low-Grade Diffuse Glioma

Ohgaki, H. (2013) · Springer eBooks · doi:10.1007/978-1-4471-2213-5_5